Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 27,007	$ 117,453
Marketable securities	71,475	0
Prepaid expenses and other current assets	1,942	2,142
Total current assets	100,924	119,595
Restricted cash equivalents	500	0
Property and equipment, net	6,038	4,612
Operating lease right-of-use asset	1,065	0
Total assets	108,027	124,207
Current liabilities:
Accounts payable	1,460	1,080
Related party payable	53	126
Accrued expenses	2,296	1,434
Operating lease liability, current portion	1,006	0
Total current liabilities	4,815	2,640
Operating lease liability, less current portion	59	0
Long-term debt	29,149	0
Total liabilities	34,023	2,640
Commitments and contingencies (Note 12)
Stockholders' equity:
Preferred stock, $0.0001 par value - 20,000 shares authorized; none issued and outstanding as of December 31, 2022 and December 31, 2021	0	0
Additional paid-in capital	75,842	55,737
Accumulated other comprehensive loss	(73)	0
Accumulated deficit	(38,919)	(8,331)
Total stockholders' equity attributable to Rani Therapeutics Holdings, Inc.	36,855	47,411
Non-controlling interest	37,149	74,156
Total stockholders' equity	74,004	121,567
Total liabilities and stockholders' equity	108,027	124,207
Common Class A [Member]
Stockholders' equity:
Common stock, value	3	2
Common Class B [Member]
Stockholders' equity:
Common stock, value	2	3
Common Class C
Stockholders' equity:
Common stock, value	$ 0	$ 0